Company release
17.01 Finnish time / 16.01 Swedish time
Person subject to the notification requirement
Position: Member of the Board/Deputy member
Issuer:
LEI: 743700JJO2NU8LBS1592
Notification type: INITIAL NOTIFICATION
Reference number: 65899/19/10
Transaction date: 2024-06-14
Outside a trading venue
Instrument type: SHARE
ISIN: FI4000330972
Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE
Transaction details
(1): Volume: 19402 Unit price:
Aggregated transactions (1):
Volume: 19402 Volume weighted average price:
For further information, please contact:
General Counsel
peter.hanninen@nanoform.com
+358 50 353 0408
For investor relations queries, please contact:
Director of Investor Relations
hvh@nanoform.com
+46 7686 650 11
About NanoformNanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP nano-API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services, from pre-clinical to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in
https://news.cision.com/nanoform/r/nanoform-finland-plc---manager-s-transactions---jeanne-thoma,c4001640
https://mb.cision.com/Main/18905/4001640/2866593.pdf
(c) 2024 Cision. All rights reserved., source